ArticleMaterials today. Bio2026
Intelligent nanoliposome ameliorate chronic intermittent hypoxia-mediated neuronal injury via a dual regulation microglial inflammation strategy.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reduced microvascular coverage links a hypoxia-associated niche to microglial autophagic dysfunction in Parkinson's disease.Acta neuropathologica communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The etiology of obstructive sleep apnea syndrome (OSAS)-associated cognitive dysfunction is unclear and complex. There is growing evidence demonstrate that hyper-activated neuroinflammation, M1 phenotypic microglia polarization, and subsequent neuronal inflammatory damage induced by chronic intermittent hypoxia (CIH) pose a crucial role in OSAS-related cognitive dysfunction. However, the regulatory mechanisms remain unclear, and during treatment, there are inevitable issues with small molecule drugs such as hydrophobicity, lack of targeting, and uncontrolled dosages, especially their inability to cross the blood-brain barrier (BBB), which severely hinders the treatment of CIH related cognitive dysfunction. Herein, a "dual regulation" microglial inflammation strategy was proposed using intelligent nanoliposomes (Ang-Lip@BAY/GW1929), capable of simultaneously regulating PPARγ signaling and IκBα/p65 pathway to reverse the inflammatory microglia transformation. The cationic Ang-Lip@BAY/GW1929 was innovatively used for the dual-targeted identification of CIH-activated microglia that highly express LRP-1 and carry a negative surface charge, to achieve efficient delivery and release of drugs. Simultaneously, PPARγ agonist (GW1929), and IκBα phosphorylation inhibitor (BAY) were delivered from ROS-responsive Ang-Lip@BAY/GW1929 to coordinate the inhibition of NF-κB pathway through PPARγ and IκBα/p65 signaling to systemically regulate microglial polarization, neuroinflammation, neuronal damage, and cognitive dysfunction. Collectively, the study proposed strategies for building bio-targeted liposome-based nanovector to relieve CIH-induced neuron injury, and systematically described treatment mechanisms on CIH related impairment, opening a new path for the treatment of CIH related cognitive dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.